Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization

FHS
June 22, 2024
6:24 am

Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the

September 23, 2024

Writing health AI rules: Why Micky Tripathi faces one of the toughest jobs in Washington

One muggy Washington afternoon in late September, Micky Tripathi faced a small crowd in a Capitol Hill row house, ready to launch into a couple

October 1, 2024

Medscape Launches Free AI Medical Scribe for Physicians

What You Should Know: – Medscape has launched a free AI medical scribe for US physicians, the latest entry in a developing space of artificial intelligence tools

August 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.